ClinicalTrials.gg
CompletedNCT01843348ATHENAUpdated May 1, 2017Results posted

12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients

A Phase 3 interventional study of Everolimus and Tacrolimus in Kidney Transplantation and Renal Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 27 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-01.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2012, registered Apr 2013).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
612
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing tacrolimus in Graft vs Host Disease — 3 open to participants now, 4 under way, none of them phase 3. Tacrolimus · Graft vs Host Disease.

Enrollment
Largest of 32
612 · median 34
Started
2012
with 2 others
Phase 3
2 of 36
none open now
Registered
28th of 36
by date
Lead sponsor
2 of 36
Novartis Pharmaceuticals

Among the 36 studies testing tacrolimus in Graft vs Host Disease, this one has the largest enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2012, is one of 2 in phase 3, and was the 28th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

3 of the 36 studies testing tacrolimus in Graft vs Host Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tacrolimus

Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing tacrolimus in Graft vs Host Disease, or all of them as a file.
02

Study summary

This study was designed to evaluate the renal function comparing Certican based immunosuppressive regimens with two different CNIs (Tacrolimus or Cyclosporin A) versus a standard treatment with Mycophenolic Acid and Tacrolimus in de novo renal transplant recipients.

03

Conditions studied

  • Kidney Transplantation
  • Renal Transplantation

Browse trials for

Keywords

  • Transplant
  • Renal transplant
  • Rejection,allograf
  • Rejection
  • Xenograft rejection
  • Host vs graft disease
  • Kidney Transplant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient who had received a primary or secondary kidney transplant
  • Patients who were willing and from whom written was obtained
  • kidney allograft with a cold ischemia time (CIT) \< 30 hours
  • negative pregnancy test prior to study enrollment

Exclusion criteria

Exclusion Criteria:

--Multi-organ recipients

  • former Graft loss due to immunological reasons
  • Patients who received a kidney from a non-heart beating donor
  • A-B-0 incompatible transplants
  • a current Panel Reactive Antibody (PRA) level of > 20%
  • existing antibodies against the HLA-type of the receiving transplant
  • a known / to any of the
  • Use of other drugs
  • Patients with thrombocytopenia ( \< 100,000/mm³), with an of \< 2,000/mm³ or leucopenia (leucocytes \< 3,000/mm³), or \< 8 g/dL
  • significant mental illness
  • history of during the last five years
  • positive
  • uncontrolled hypercholesterolemia or hypertriglyceridemia
  • drug or alcohol abuse
  • pregnant or breast feeding women
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
612 participants (actual)

Study arms

  • Active comparator
    TAC+MPA

    Drug: Tacrolimus · Drug: Enteric Coated Mycophenolate Sodium (EC-MPS) · Drug: Mycophenolate mofetil (MMF) · Drug: Corticosteroids · Drug: Simulect

  • Experimental
    TAC+Certican

    Drug: Everolimus · Drug: Tacrolimus · Drug: Corticosteroids · Drug: Simulect

  • Experimental
    CycA+Certican

    Drug: Everolimus · Drug: Cyclosporin A · Drug: Corticosteroids · Drug: Simulect

Interventions

  • Also known as: Certican

  • Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels

  • Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml

  • Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose

  • Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose

  • DrugCorticosteroids

    A minimum dose of 5 mg prednisolon or equivalent

  • Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.

    Also known as: Basiliximab

06

What researchers measure

Primary outcomes

  1. Glomular Filtration Rate (GFR) mL/Min Via Nankivell Method at Month 12 - Standard Regimen vs Certican Regimens

    To demonstrate non-inferiority in renal function assessed by glomerular filtration rate (Nankivell formula) in at least one of the Certican® treatment regimens compared to the standard regimen group at month 12 post-transplantation in renal transplant patients. Nankivell formula: GFR = 6.7/Scr + BW/4 - Surea/2 - 100/(height)² + C where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kg, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The eGFR is expressed in mL/min per 1.73m². If a patient was on dialysis at the time of urea or creatinine assessment, the eGFR was set to 0. Analysis set = per protocol set

    Time frame: One year post transplant

Secondary outcomes

  1. Percentage of Participants With Composite Treatment Failure Endpoints - Difference Between Groups at Month 12

    Combined endpoint included: biopsy proven acute rejection (BPAR) defined as a rejection which was acute and proven by biopsy, graft loss (GL) defined as: allograft was presumed to be lost on the day the patient starts dialysis and not able to be removed from dialysis or death. Patients who prematurely discontinued the study: if the patient did not suffer from an event before discontinuation and reason was not related to efficacy, the patient was assessed as having had no event, otherwise the patient was assessed as having had an event. Full analysis set (FAS)

    Time frame: Month 12 post transplant

  2. Glomular Filtration Rate (GFR) Via Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Method at Month 12 Post Transplant

    Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method = GFR=141 x min(Scr/κ, 1)α x max(Scr/κ, 1)1.209 x 0.993Age x 1.018 \[if female\] x 1.159 \[if black\] where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is 0.329 for females and 0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model

    Time frame: Month 12 post transplant

  3. Glomular Filtration Rate (GFR) mL/Min Via Cockcroft- Gault Method at Month 12 Post Transplant

    Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl)For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model

    Time frame: Month 12 post transplant

  4. Glomular Filtration Rate (GFR) Via Modification of Diet in Renal Disease (MDRD) Method at Month 12 Post Transplant

    Modification of Diet in Renal Disease (MDRD) = For men: GFR = 170 x (serum creatinine -0,999) x (age-0,176) x (urea nitrogen -0,17) x (albumin0,318) For women: GFR = 170 x (serum creatinine -0,999) x (age-0,176) x (urea nitrogen -0,17) x albumin0,318) x 0.762 with urea nitrogen = urea / 2.144. last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model

    Time frame: Month 12 post transplant

  5. Percentage of Participants With Treatment Failure Endpoints at Month 12

    Treatment failure endpoints: biopsy proven acute rejection (BPAR) defined as a rejection which was acute and proven by biopsy, graft loss (GL) defined as: allograft was presumed to be lost on the day the patient starts dialysis and not able to be removed from dialysis or death. Patients who prematurely discontinued the study: if the patient did not suffer from an event before discontinuation and reason was not related to efficacy, the patient was assessed as having had no event, otherwise the patient was assessed as having had an event. Full analysis set (FAS)

    Time frame: Month 12 post transplant

  6. Percent of Participants With Delayed Graft Function and Slow Graft Function

    Delayed graft function (DGF) was defined as the need for dialysis within the first 7 days post-transplantation, excluding the first post-transplantation day. Slow graft function (SGF) was defined as a serum creatinine \>3.0 mg/dL at Day 5 post-transplantation. Full analysis set

    Time frame: Post transplant to month 12

  7. Percent of Participants With Delayed Graft Function by Day

    Delayed graft function (DGF) was defined as the need for dialysis within the first 7 days post-transplantation, excluding the first post-transplantation day.

    Time frame: Post transplant up to day 7

  8. Percent of Participants With Viral Infections

    Viral infections for BKV Virus Humane Polyomavirus 1 and Cytomegalovirus

    Time frame: Post transplant to month 12

  9. Percent of Participants With Wound Healing Complications During Study

    Information collected to report wound healing process which included percentage of participants with complications, fluid collections detected and occurrence of lymphoceles

    Time frame: Post transplant until individual reporting

  10. Duration of Wound Healing

    A wound will be considered healed if all the suture material and staples are removed and the wound is intact. Number of participants is based on all patients of the respective treatment group in the safety set, excluding patients with no answer (unknown).

    Time frame: Post transplant until individual reporting

07

Results

Posted May 1, 2017

Participant flow

Participant flow — Overall Study
MilestoneTAC+MPATAC+CerticanCycA+Certican
Started205208199
Safety analysis set (sas)204210198
Full analysis set (fas)205208199
Per protocol set (pps)14711180
Completed182168158
Not completed234041
Withdrew: Withdrawal by subject41618
Withdrew: Lost to follow-up542
Withdrew: Death534
Withdrew: Graft loss/retransplantation5811
Withdrew: Various reasons496

Outcome measures

PrimaryGlomular Filtration Rate (GFR) mL/Min Via Nankivell Method at Month 12 - Standard Regimen vs Certican Regimens

To demonstrate non-inferiority in renal function assessed by glomerular filtration rate (Nankivell formula) in at least one of the Certican® treatment regimens compared to the standard regimen group at month 12 post-transplantation in renal transplant patients. Nankivell formula: GFR = 6.7/Scr + BW/4 - Surea/2 - 100/(height)² + C where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kg, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The eGFR is expressed in mL/min per 1.73m². If a patient was on dialysis at the time of urea or creatinine assessment, the eGFR was set to 0. Analysis set = per protocol set

Time frame:
One year post transplant
Reported as:
Mean · mL/min per 1.73m²
Glomular Filtration Rate (GFR) mL/Min Via Nankivell Method at Month 12 - Standard Regimen vs Certican Regimens
mL/min per 1.73m²TAC+MPATAC+CerticanCycA+Certican
Month 1 - Day 1 to 60 (146,111,78)62.62 ± 16.93160.54 ± 17.31059.47 ± 16.754
Month 3 - Day 61 to 136 (143,108,79)66.36 ± 16.67261.21 ± 14.77162.22 ± 16.196
Month 6 - Day 137 to 228 (142,108,76)68.05 ± 16.99462.76 ± 16.76363.17 ± 16.789
Month 9 - Day 229 to 319 (140,106,77)69.47 ± 16.25164.68 ± 15.50762.89 ± 14.947
Month12 - Day 320 to 450 (147,111, 80)70.41 ± 16.51463.34 ± 16.98661.51 ± 16.942
Statistical analysis
  • TAC+MPA vs CycA+Certican · ANOVA · p = <0.0001 · Least square mean: -9.35 · 95% CI -13.82 to -4.88
  • TAC+MPA vs TAC+Certican · ANOVA · p = 0.0067 (Analysis of variance (ANOVA) with tx, center, donor type factors. Raw and adjusted means were presented with one-sided p-values for un-shifted and shifted hypothesis, respectively. Significance level = 2.5% (one-sided)) · Least squares mean: -5.56 · 95% CI -9.56 to -1.55
SecondaryPercentage of Participants With Composite Treatment Failure Endpoints - Difference Between Groups at Month 12

Combined endpoint included: biopsy proven acute rejection (BPAR) defined as a rejection which was acute and proven by biopsy, graft loss (GL) defined as: allograft was presumed to be lost on the day the patient starts dialysis and not able to be removed from dialysis or death. Patients who prematurely discontinued the study: if the patient did not suffer from an event before discontinuation and reason was not related to efficacy, the patient was assessed as having had no event, otherwise the patient was assessed as having had an event. Full analysis set (FAS)

Time frame:
Month 12 post transplant
Reported as:
Number · Percentage of participants
Percentage of Participants With Composite Treatment Failure Endpoints - Difference Between Groups at Month 12
Percentage of participantsTAC+MPATAC+CerticanCycA+CerticanTac+Certican - Tac+MPA - Difference Between GroupsCycA+Certican -Tac+MPA - Difference Between Groups
BPAR or graft loss or death9.813.024.63.214.9
BPAR, graft loss, death, or loss of follow-up15.622.632.77.017.1
Statistical analysis
  • TAC+MPA vs TAC+Certican · Point estimate: 0.032 · 95% CI -0.029 to 0.093
  • TAC+MPA vs CycA+Certican · Point estimate: 0.149 · 95% CI 0.076 to 0.221
SecondaryGlomular Filtration Rate (GFR) Via Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Method at Month 12 Post Transplant

Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method = GFR=141 x min(Scr/κ, 1)α x max(Scr/κ, 1)1.209 x 0.993Age x 1.018 \[if female\] x 1.159 \[if black\] where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is 0.329 for females and 0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model

Time frame:
Month 12 post transplant
Reported as:
Least squares mean · mL/min per 1.73m²
Glomular Filtration Rate (GFR) Via Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Method at Month 12 Post Transplant
mL/min per 1.73m²TAC+MPATAC+CerticanCycA+Certican
Glomular Filtration Rate (GFR) Via Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Method at Month 12 Post Transplant51.62 (48.10 to 55.14)44.42 (40.95 to 47.89)42.44 (38.89 to 45.99)
SecondaryGlomular Filtration Rate (GFR) mL/Min Via Cockcroft- Gault Method at Month 12 Post Transplant

Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl)For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model

Time frame:
Month 12 post transplant
Reported as:
Least squares mean · mL/min per 1.73m²
Glomular Filtration Rate (GFR) mL/Min Via Cockcroft- Gault Method at Month 12 Post Transplant
mL/min per 1.73m²TAC+MPATAC+CerticanCycA+Certican
Glomular Filtration Rate (GFR) mL/Min Via Cockcroft- Gault Method at Month 12 Post Transplant60.26 (55.85 to 64.68)52.25 (47.88 to 56.61)51.30 (46.85 to 55.74)
SecondaryGlomular Filtration Rate (GFR) Via Modification of Diet in Renal Disease (MDRD) Method at Month 12 Post Transplant

Modification of Diet in Renal Disease (MDRD) = For men: GFR = 170 x (serum creatinine -0,999) x (age-0,176) x (urea nitrogen -0,17) x (albumin0,318) For women: GFR = 170 x (serum creatinine -0,999) x (age-0,176) x (urea nitrogen -0,17) x albumin0,318) x 0.762 with urea nitrogen = urea / 2.144. last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model

Time frame:
Month 12 post transplant
Reported as:
Least squares mean · mL/min per 1.73m²
Glomular Filtration Rate (GFR) Via Modification of Diet in Renal Disease (MDRD) Method at Month 12 Post Transplant
mL/min per 1.73m²TAC+MPATAC+CerticanCycA+Certican
Glomular Filtration Rate (GFR) Via Modification of Diet in Renal Disease (MDRD) Method at Month 12 Post Transplant53.24 (49.62 to 56.87)45.72 (42.11 to 49.32)43.47 (39.75 to 47.20)
SecondaryPercentage of Participants With Treatment Failure Endpoints at Month 12

Treatment failure endpoints: biopsy proven acute rejection (BPAR) defined as a rejection which was acute and proven by biopsy, graft loss (GL) defined as: allograft was presumed to be lost on the day the patient starts dialysis and not able to be removed from dialysis or death. Patients who prematurely discontinued the study: if the patient did not suffer from an event before discontinuation and reason was not related to efficacy, the patient was assessed as having had no event, otherwise the patient was assessed as having had an event. Full analysis set (FAS)

Time frame:
Month 12 post transplant
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Failure Endpoints at Month 12
Percentage of participantsTAC+MPATAC+CerticanCycA+Certican
Biopsy proven acute rejection (BPAR)9.312.024.6
Treated BPAR (tBPAR)8.811.523.6
Graft loss5.46.39.0
Death4.96.36.5
Statistical analysis
  • TAC+MPA vs TAC+Certican · Pearson's chi-square test · p = < 0.001 · Odds ratio, log: 0.028 · 95% CI -0.032 to 0.087
SecondaryPercent of Participants With Delayed Graft Function and Slow Graft Function

Delayed graft function (DGF) was defined as the need for dialysis within the first 7 days post-transplantation, excluding the first post-transplantation day. Slow graft function (SGF) was defined as a serum creatinine \>3.0 mg/dL at Day 5 post-transplantation. Full analysis set

Time frame:
Post transplant to month 12
Reported as:
Number · Percent of participants
Percent of Participants With Delayed Graft Function and Slow Graft Function
Percent of participantsTAC+MPATAC+CerticanCycA+Certican
Delayed graft function (197,187,172)17.820.322.1
Slow graft function (195,187,171)46.248.749.7
SecondaryPercent of Participants With Delayed Graft Function by Day

Delayed graft function (DGF) was defined as the need for dialysis within the first 7 days post-transplantation, excluding the first post-transplantation day.

Time frame:
Post transplant up to day 7
Reported as:
Number · Percent of participants
Percent of Participants With Delayed Graft Function by Day
Percent of participantsTAC+MPATAC+CerticanCycA+Certican
day 1 (8,7,4)22.918.410.5
day 2 (2,2,2)5.75.35.3
day 3 (5,1,2)14.32.65.3
day 4 (4,2,4)11.45.310.5
day 5 (4,5,3)11.413.27.9
day 6 (1,1,2)2.92.65.3
day 7 (2,4,0)5.710.50.0
>7 days (9,16,21)25.742.155.3
SecondaryPercent of Participants With Viral Infections

Viral infections for BKV Virus Humane Polyomavirus 1 and Cytomegalovirus

Time frame:
Post transplant to month 12
Reported as:
Number · Percent of participants
Percent of Participants With Viral Infections
Percent of participantsTAC+MPATAC+CerticanCycA+Certican
Viral infections - CMVMissing1.00.01.0
Viral infections - CMVAsymptomatic7.01.01.0
Viral infections - CMVMild5.02.01.0
Viral infections - CMVModerate6.01.01.0
Viral infections - CMVSevere1.00.00.0
Viral infections - BKVAsymptomatic10.08.05.0
Viral infections - BKVMild5.07.03.0
Viral infections - BKVModerate7.02.01.0
Viral infections - BKVSevere000
SecondaryPercent of Participants With Wound Healing Complications During Study

Information collected to report wound healing process which included percentage of participants with complications, fluid collections detected and occurrence of lymphoceles

Time frame:
Post transplant until individual reporting
Reported as:
Number · Percent of participants
Percent of Participants With Wound Healing Complications During Study
Percent of participantsTAC+MPATAC+CerticanCycA+Certican
Wound healing complication14.319.122.2
Fluids detected18.726.827.8
Occurrence of lymphoceles11.818.221.8
SecondaryDuration of Wound Healing

A wound will be considered healed if all the suture material and staples are removed and the wound is intact. Number of participants is based on all patients of the respective treatment group in the safety set, excluding patients with no answer (unknown).

Time frame:
Post transplant until individual reporting
Reported as:
Mean · days
Duration of Wound Healing
daysTAC+MPATAC+CerticanCycA+Certican
Duration of Wound Healing42.4 ± 41.1354.1 ± 61.9785.3 ± 62.7

Adverse events

Collected over Timeframe for AE. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tac+MPA—135/204 (66.2%)200/204 (98%)
Tac+Certican—161/210 (76.7%)205/210 (97.6%)
CycA+Certican—144/198 (72.7%)196/198 (99%)
Most frequent serious events
Showing 10 of 352
Most frequent serious events
EventTac+MPATac+CerticanCycA+Certican
Urinary tract infectionInfections and infestations21/20427/21016/198
LymphoceleVascular disorders12/20419/21024/198
Kidney transplant rejectionImmune system disorders8/20419/21022/198
Complications of transplanted kidneyInjury, poisoning and procedural complications18/20422/21018/198
Blood creatinine increasedInvestigations11/20420/21019/198
Transplant rejectionImmune system disorders8/2045/21017/198
Acute kidney injuryRenal and urinary disorders9/20412/2107/198
Renal transplant failureImmune system disorders8/2049/21011/198
Cytomegalovirus infectionInfections and infestations11/2042/2102/198
PyelonephritisInfections and infestations10/2049/2108/198
Most frequent other events
Showing 10 of 69
Most frequent other events
EventTac+MPATac+CerticanCycA+Certican
Oedema peripheralGeneral disorders62/20482/21099/198
ConstipationGastrointestinal disorders71/20469/21081/198
Urinary tract infectionInfections and infestations81/20474/21072/198
Wound complicationInjury, poisoning and procedural complications68/20464/21056/198
HyperkalaemiaMetabolism and nutrition disorders65/20453/21058/198
HypertensionVascular disorders52/20462/21057/198
AnaemiaBlood and lymphatic system disorders44/20453/21058/198
Diarrhoea infectiousInfections and infestations56/20440/21029/198
NauseaGastrointestinal disorders46/20444/21042/198
BK virus infectionInfections and infestations45/20436/21018/198

Baseline characteristics

Full analysis set consisted of all randomized patients who received at least one dose of study drug

Age, Continuous
Age, Continuous(years)TAC+MPATAC+CerticanCycA+CerticanTotal
Mean55.3 ± 12.0954.3 ± 13.5055.1 ± 12.6154.9 ± 12.74
Sex: Female, Male
Sex: Female, Male(Participants)TAC+MPATAC+CerticanCycA+CerticanTotal
Female657066201
Male140138133411
08

Study locations

27 sites
  • Novartis Investigative Site
    Bordeaux Cedex, 33076, France
  • Novartis Investigative Site
    Brest, 29200, France
  • Novartis Investigative Site
    Creteil, 94010, France
  • Novartis Investigative Site
    Dijon, 21079, France
  • Novartis Investigative Site
    Lille Cedex, 59037, France
  • Novartis Investigative Site
    Lyon, 69437, France
  • Novartis Investigative Site
    Nantes, 44035, France
  • Novartis Investigative Site
    Paris, 75970, France
  • Novartis Investigative Site
    Poitiers, 86000, France
  • Novartis Investigative Site
    St Priest en Jarez Cedex, 42277, France
  • Novartis Investigative Site
    Strasbourg, 67091, France
  • Novartis Investigative Site
    Toulouse Cedex 4, 31054, France
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bochum, 44892, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Erlangen, 91052, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
09

References and documents

Publications

  • Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Nashan B, Thaiss F. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. Trials. 2016 Feb 17;17:92. doi: 10.1186/s13063-016-1220-9. PubMed 26888217 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in Mar 2016, 38 months.

Results were first posted in May 2017, 1 year 1 month after primary completion.

Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2013
First posted
Apr 30, 2013
StartActual
Dec 27, 2012
Primary completionActual
Mar 23, 2016
CompletionActual
Mar 23, 2016
Results first posted
May 1, 2017
Last update
May 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01843348
Responsible party
Sponsor
First posted
Apr 30, 2013
Start date
Dec 27, 2012
Primary completion
Mar 23, 2016
Completion
Mar 23, 2016
Results posted
May 1, 2017
Last update
May 1, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Everolimus · Tacrolimus · Cyclosporine

Start the discussion